表紙
市場調查報告書

細胞療法的全球市場:各使用目的(臨床、研究)、種類(幹細胞、非幹細胞)、治療類型(自體移植、同類移植) - 市場規模,佔有率,市場趨勢分析 2018年∼2025年

Cell Therapy Market Size, Share & Trends Analysis Report By Use-type (Research, Commercialized, Musculoskeletal Disorders), By Therapy Type (Autologous, Allogeneic), By Region, And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 748450
出版日期 內容資訊 英文 125 Pages
商品交期: 2-3個工作天內
價格
細胞療法的全球市場:各使用目的(臨床、研究)、種類(幹細胞、非幹細胞)、治療類型(自體移植、同類移植) - 市場規模,佔有率,市場趨勢分析 2018年∼2025年 Cell Therapy Market Size, Share & Trends Analysis Report By Use-type (Research, Commercialized, Musculoskeletal Disorders), By Therapy Type (Autologous, Allogeneic), By Region, And Segment Forecasts, 2020 - 2027
出版日期: 2020年02月27日內容資訊: 英文 125 Pages
簡介

全球細胞療法市場預測從2018年到2025年將以5.34%的年複合成長率發展,到2025年市場規模將成長到79億2,000萬美元。對於應用了遺傳基因、細胞、組織的先進醫療品的開發的全球性的關心高漲,促進了這個市場的成長。

本報告提供全球細胞療法市場調查,市場概要,各使用目的、種類、治療類型、地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,波特的五力分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 摘要整理

  • 市場概述

第2章 調查方法

  • 資訊採購
  • 資訊分析
  • 市場結構與檢驗
  • 市場預測

第3章 市場變數,市場趨勢,範圍

  • 市場區隔和範圍
  • 成長預測製圖
  • SWOT分析
  • 波特的五力分析

第4章 幹細胞/非幹細胞療法市場分析與預測:各使用目的

  • 市場趨勢分析:各使用目的
  • 臨床
  • 研究

第5章 幹細胞/非幹細胞療法市場分析與預測:各移植類型

  • 市場趨勢分析:各移植類型
  • 同種異體移植
  • 自體移植

第6章 幹細胞/非幹細胞療法市場分析與預測:各地區

  • 市場佔有率分析:各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲地區

第7章 競爭情形

  • 策略的組成架構
  • 企業簡介
    • Kolon TissueGene, Inc.
    • MEDIPOST
    • Osiris Therapeutics, Inc.
    • Stemedica Cell Technologies, Inc.
    • Cells for Cells
    • NuVasive, Inc
    • Fibrocell Science, Inc.
    • Vericel Corporation
    • PHARMICELL Co., Ltd
    • ANTEROGEN.CO.,LTD
    • Celgene Corporation

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GVR-2-68038-701-8

The global cell therapy market size is expected to reach USD 8.8 billion by 2027 at a CAGR of 5.4% over the forecast period, according to a new report by Grand View Research, Inc. Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and clinical translation. Moreover, rapid advances in stem cell research hold the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. These factors have boosted revenue growth for the market.

Currently, there are a limited number of FDA-approved commercial stem and non-stem cell therapies in the market. Furthermore, LAVIV (Azficel-T), manufactured and commercialized by Fibrocell Technologies, witnessed revenue wind-down in the past years. Key developers are making substantial investments in the adoption of advanced technologies to address the aforementioned challenges.

The introduction of proprietary cell lines is recognized as the primary means by which a single cell can be exploited for the production of a robust portfolio of candidates. Companies are leveraging new technologies not only for the expansion of their product portfolio but also for establishing out-licensing or co-development agreements with other entities to support their product development programs.

For instance, MaxCyte has more than 40 high-value cellular therapy partnership programs within immune-oncology, regenerative medicine, and gene editing, including fifteen clinical-stage programs. Increase in the number of collaborations between entities for product commercialization is anticipated to accelerate market revenue to a major extent in the coming years.

In Asia Pacific, the market is anticipated to witness significant growth over the forecast period. This is attributed to rising awareness cellular therapies among patients and healthcare entities in chronic disease management. In addition, availability of therapeutic treatment at lower prices is also driving the regional market. Japan is likely to witness fast growth over the forecast period attributed to increasing research activities on regenerative medicine.

Further key findings from the report suggest:

  • The clinical-use segment accounted for low revenue share due to stringent regulations and non- commercial viability of some products
  • However, the expanding knowledge over the commercial potential of cellular therapies is anticipated to result in the commercialization of a large number of products in the coming years
  • On the contrary, the research-use segment accounted for the largest revenue share in 2019 owing to increase in research activities to explore the potential of the therapy in substantially improving disease management
  • Furthermore, an increase in funding to explore the potential of these therapies has contributed to the large share of the research segment
  • Allogenic therapies dominated the revenue share in 2019 owing to relatively lower relapse rates and growth in stem cell banking activities
  • This is due to the high price and a large number of companies involved in the development of allogenic therapies
  • Moreover, several companies are preparing to shift their business towards allogeneic therapy product development, resulting in significant revenue growth in this segment
  • Autologous therapies are estimated to grow at the fastest pace during the forecast period
  • Lack of donors and low affordability of allogeneic therapies are two key factors contributing to the increase in adoption of autologous therapies
  • Considering the growing share of the cell therapy market in the biopharma industry, the companies are striving to gain a competitive advantage
  • Vericel Corporation, JCR Pharmaceuticals Co. Ltd., MEDIPOST, and Osiris Therapeutics, Inc. are some key players operating in the market
  • These companies are engaged in the expansion of their product portfolio, either through product development or acquisition of other players operating in the space.

Table of Content

Chapter 1 Executive Summary

  • 1.1 Market Snapshot

Chapter 2 Research Methodology

  • 2.1 Information Procurement
    • 2.1.1 Purchased Database
    • 2.1.2 GVR's Internal Database
  • 2.2 Data Analysis
  • 2.3 Market Formulation & Validation
  • 2.4 Approaches for Market Estimation
    • 2.4.1 Approach 1: Commodity Flow & Bottom Up Approach
    • 2.4.2 Approach 2: Top Down and Parent Market Analysis

Chapter 3 Cell Therapy Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Rise in number of clinical studies pertaining to the development of cellular therapies
      • 3.1.1.2 Rising adoption of regenerative medicine
      • 3.1.1.3 Introduction of novel platforms and technologies
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 Ethical concerns related to stem cell research
      • 3.1.2.2 Clinical issues pertaining to development & implementation of cell therapy
      • 3.1.2.2.1 Manufacturing issues
      • 3.1.2.2.2 Genetic instability
      • 3.1.2.2.3 Stem cell culture condition
      • 3.1.2.2.4 Stem cell distribution after transplant
      • 3.1.2.2.5 Immunological rejection
      • 3.1.2.2.6 Challenges associated with allogeneic mode of transplantation
  • 3.2 Penetration & Growth Prospect Mapping For Therapy Type, 2019
  • 3.3 Cell Therapy Market (Stem & Non-stem Cells)-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.4 Industry Analysis - Porter's
  • 3.5 Cell Therapy Market (Stem & Non-stem Cells)-Regulatory Landscape

Chapter 4 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Use-type Estimates & Trend Analysis

  • 4.1 Cell Therapy Market (Stem & Non-stem Cells): Use-type Movement Analysis
  • 4.2 Clinical-use
    • 4.2.1 Global cell therapy market (stem & non-stem cells) for clinical-use, 2016 - 2027 (USD Million)
    • 4.2.2 Cell therapy market (stem & non-stem cells) for clinical-use, by therapeutic area
      • 4.2.2.1 Malignancies
      • 4.2.2.1.1 Global cell therapy market (stem & non-stem cells) for malignancies, 2016 - 2027 (USD Million)
      • 4.2.2.2 Musculoskeletal disorders
      • 4.2.2.2.1 Global cell therapy market (stem & non-stem cells) for Musculoskeletal disorders, 2016 - 2027 (USD Million)
      • 4.2.2.3 Autoimmune disorders
      • 4.2.2.3.1 Global cell therapy market (stem & non-stem cells) for autoimmune disorders, 2016 - 2027 (USD Million)
      • 4.2.2.4 Dermatology
      • 4.2.2.4.1 Global cell therapy market (stem & non-stem cells) for dermatology, 2016 - 2027 (USD Million)
      • 4.2.2.5 Others
      • 4.2.2.5.1 Global cell therapy market (stem & non-stem cells) for other therapeutic areas, 2016 - 2027 (USD Million)
    • 4.2.3 Cell therapy market (stem & non-stem cells) for clinical-use, by cell type
      • 4.2.3.1 Stem cell therapies
      • 4.2.3.1.1 Global stem cell therapies market, 2016 - 2027 (USD Million)
      • 4.2.3.1.2 Bone marrow, blood, & umbilical cord-derived stem cell therapies
      • 4.2.3.1.3 Adipose-derived stem cell therapies
      • 4.2.3.1.4 Other stem cell therapies
      • 4.2.3.2 Non-stem cell therapies
      • 4.2.3.2.1 Global non-stem cell therapies market, 2016 - 2027 (USD Million)
  • 4.3 Research-use
    • 4.3.1 Global cell therapy market (stem & non-stem cells) for research-use, 2016 - 2027 (USD Million)

Chapter 5 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Therapy Type Estimates & Trend Analysis

  • 5.1 Cell Therapy Market (Stem & Non-stem Cells): Therapy Type Movement Analysis
  • 5.2 Allogeneic Therapies
    • 5.2.1 Global cell therapy market (stem & non-stem cells) for allogeneic therapies, 2016 - 2027 (USD Million)
  • 5.3 Autologous Therapies
    • 5.3.1 Global cell therapy market (stem & non-stem cells) for autologous therapies, 2016 - 2027 (USD Million)

Chapter 6 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Regional Estimates & Trend Analysis, by Product

  • 6.1 Cell Therapy Market (Stem & Non-stem Cells) Share By Regional, 2019 & 2027
  • 6.2 North America
    • 6.2.1 North America cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 U.S. cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
      • 6.2.2.2 U.S. cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Canada cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
      • 6.2.3.2 Canada cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
    • 6.3.2 Germany
      • 6.3.2.1 Germany cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
      • 6.3.2.2 Germany cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
    • 6.3.3 U.K.
      • 6.3.3.1 U.K. cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
      • 6.3.3.2 U.K. cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
    • 6.4.2 China
      • 6.4.2.1 China cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
      • 6.4.2.2 China cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
    • 6.4.3 Japan
      • 6.4.3.1 Japan cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
      • 6.4.3.2 Japan cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Brazil cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
      • 6.5.2.2 Brazil cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)
  • 6.6 MEA
    • 6.6.1 MEA cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 South Africa cell therapy market (stem & non-stem cells), by use-type, 2016 - 2027 (USD Million)
      • 6.6.2.2 South Africa cell therapy market (stem & non-stem cells), by therapy type, 2016 - 2027 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy Framework
  • 7.2 Company Profiles
    • 7.2.1 Kolon TissueGene, Inc.
      • 7.2.1.1 Company overview
      • 7.2.1.2 Financial performance
      • 7.2.1.3 Product benchmarking
      • 7.2.1.4 Strategic initiatives
    • 7.2.2 JCR Pharmaceuticals Co., Ltd.
      • 7.2.2.1 Company overview
      • 7.2.2.2 Financial performance
      • 7.2.2.2.1 Financial performance of TEMCELL HS Inj
      • 7.2.2.3 Product benchmarking
      • 7.2.2.4 Strategic initiatives
    • 7.2.3 MEDIPOST
      • 7.2.3.1 Company overview
      • 7.2.3.2 Financial performance
      • 7.2.3.3 Product benchmarking
      • 7.2.3.4 Strategic initiatives
    • 7.2.4 Osiris Therapeutics, Inc.
      • 7.2.4.1 Company overview
      • 7.2.4.2 Financial performance
      • 7.2.4.3 Product benchmarking
    • 7.2.5 Stemedica Cell Technologies, Inc.
      • 7.2.5.1 Company overview
      • 7.2.5.2 Financial performance
      • 7.2.5.3 Product benchmarking
      • 7.2.5.4 Strategic initiatives
    • 7.2.6 Cells for Cells
      • 7.2.6.1 Company overview
      • 7.2.6.2 Financial performance
      • 7.2.6.3 Product benchmarking
    • 7.2.7 NuVasive, Inc
      • 7.2.7.1 Company overview
      • 7.2.7.2 Financial performance
      • 7.2.7.3 Product benchmarking
    • 7.2.8 Fibrocell Science, Inc.
      • 7.2.8.1 Company overview
      • 7.2.8.2 Financial performance
      • 7.2.8.3 Product benchmarking
      • 7.2.8.4 Strategic initiatives
    • 7.2.9 Vericel Corporation
      • 7.2.9.1 Company overview
      • 7.2.9.2 Financial performance
      • 7.2.9.3 Product benchmarking
      • 7.2.9.4 Strategic initiatives
    • 7.2.10 PHARMICELL Co., Ltd
      • 7.2.10.1 Company overview
      • 7.2.10.2 Financial performance
      • 7.2.10.3 Product benchmarking
      • 7.2.10.4 Strategic initiatives
    • 7.2.11 ANTEROGEN.CO.,LTD
      • 7.2.11.1 Company overview
      • 7.2.11.2 Financial performance
      • 7.2.11.3 Product benchmarking
      • 7.2.11.4 Strategic initiatives
    • 7.2.12 Celgene Corporation
      • 7.2.12.1 Company overview
      • 7.2.12.2 Financial performance
      • 7.2.12.3 Product benchmarking
      • 7.2.12.4 Strategic Initiatives

List of Tables

  • TABLE 1 Characteristics of 1,052 registered stem cell clinical trials and 286 trials that published primary outcome data in 333 publications with respect to status, phase, graft type, cell type, country, & funding, May 2017
  • TABLE 2 Some regenerative medicine FDA-approved products
  • TABLE 3 North America cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 4 North America cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 5 North America cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 6 North America stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 7 North America cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 8 U.S. cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 9 U.S. cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 10 U.S. cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 11 U.S. stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 12 U.S. cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 13 Canada cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 14 Canada cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 15 Canada cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 16 Canada stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 17 Canada cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 18 Europe cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 19 Europe cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 20 Europe cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 21 Europe stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 22 Europe cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 23 Germany cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 24 Germany cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 25 Germany cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 26 Germany stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 27 Germany cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 28 U.K. cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 29 U.K. cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 30 U.K. cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 31 U.K. stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 32 U.K. cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 33 Asia Pacific cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 34 Asia Pacific cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 35 Asia Pacific cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 36 Asia Pacific stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 37 Asia Pacific cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 38 Japan cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 39 Japan cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 40 Japan cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 41 Japan stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 42 Japan cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 43 China cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 44 China cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 45 China cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 46 China stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 47 China cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 48 Latin America cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 49 Latin America cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 50 Latin America cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 51 Latin America stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 52 Latin America cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 53 Brazil cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 54 Brazil cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 55 Brazil cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 56 Brazil stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 57 Brazil cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 58 MEA cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 59 MEA cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 60 MEA cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 61 MEA stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 62 MEA cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
  • TABLE 63 South Africa cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
  • TABLE 64 South Africa cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
  • TABLE 65 South Africa cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 66 South Africa stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
  • TABLE 67 South Africa cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Therapeutic delivery methods investigated in preclinical research in 2017, U.K.
  • FIG. 12 Some future key trends in regenerative medicine
  • FIG. 13 Market restraint relevance analysis (Current & future impact)
  • FIG. 14 Penetration & growth prospect mapping for therapy, 2019
  • FIG. 15 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 16 Porter's Five Forces Analysis
  • FIG. 17 Cell therapy market (stem & non-stem cells): Use-type outlook key takeaways
  • FIG. 18 Global cell therapy market (stem & non-stem cells): Use-type movement analysis
  • FIG. 19 Global cell therapy market (stem & non-stem cells) for clinical-use, 2016 - 2027 (USD Million)
  • FIG. 20 Global cell therapy market (stem & non-stem cells) for malignancies market, 2016 - 2027 (USD Million)
  • FIG. 21 Global cell therapy market (stem & non-stem cells) for Musculoskeletal disorders, 2016 - 2027 (USD Million)
  • FIG. 22 Global cell therapy market (stem & non-stem cells) for autoimmune disorders, 2016 - 2027 (USD Million)
  • FIG. 23 Global cell therapy market (stem & non-stem cells) for dermatology, 2016 - 2027 (USD Million)
  • FIG. 24 Global cell therapy market (stem & non-stem cells) for other therapeutic areas, 2016 - 2027 (USD Million)
  • FIG. 25 Global stem cell therapies market, 2016 - 2027 (USD Million)
  • FIG. 26 Global bone marrow, blood, & umbilical cord-derived stem cell therapies market, 2016 - 2027 (USD Million)
  • FIG. 27 Global adipose-derived stem cell therapies market, 2016 - 2027 (USD Million)
  • FIG. 28 Global other stem cell therapies market, 2016 - 2027 (USD Million)
  • FIG. 29 Global non-stem cell therapies market, 2016 - 2027 (USD Million)
  • FIG. 30 Global cell therapy market (stem & non-stem cells) for research-use, 2016 - 2027 (USD Million)
  • FIG. 31 Cell therapy market (stem & non-stem cells): Therapy type outlook key takeaways
  • FIG. 32 Global cell therapy market (stem & non-stem cells): Therapy type movement analysis
  • FIG. 33 Global cell therapy market (stem & non-stem cells) for allogeneic therapies, 2016 - 2027 (USD Million)
  • FIG. 34 Global cell therapy market (stem & non-stem cells) for autologous therapies, 2016 - 2027 (USD Million)
  • FIG. 35 Regional market place: Key takeaway
  • FIG. 36 Cell therapy market (stem & non-stem cells) regional outlook, 2019 & 2027
  • FIG. 37 North America cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 38 U.S. cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 39 Canada cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 40 Europe cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 41 Germany cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 42 U.K. cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 43 Asia Pacific cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 44 Japan cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 45 China cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 46 Latin America cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 47 Brazil cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 48 MEA cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 49 South Africa cell therapy market (stem & non-stem cells), 2016 - 2027 (USD Million)
  • FIG. 50 Strategy framework
  • FIG. 51 Market participants categorization